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Abstract
Epstein-Barr Virus (EBV) is an oncogenic c-herpesvirus that capably establishes both latent and lytic modes of infection in
host cells and causes malignant diseases in humans. Nuclear antigen 2 (EBNA2)-mediated transcription of both cellular and
viral genes is essential for the establishment and maintenance of the EBV latency program in B lymphocytes. Here, we
employed a protein affinity pull-down and LC-MS/MS analysis to identify nucleophosmin (NPM1) as one of the cellular
proteins bound to EBNA2. Additionally, the specific domains that are responsible for protein-protein interactions were
characterized as EBNA2 residues 300 to 360 and the oligomerization domain (OD) of NPM1. As in c-MYC, dramatic NPM1
expression was induced in EBV positively infected B cells after three days of viral infection, and both EBNA2 and EBNALP
were implicated in the transactivation of the NPM1 promoter. Depletion of NPM1 with the lentivirus-expressed short-hairpin
RNAs (shRNAs) effectively abrogated EBNA2-dependent transcription and transformation outgrowth of lymphoblastoid
cells. Notably, the ATP-bound state of NPM1 was required to induce assembly of a protein complex containing EBNA2, RBP-
Jk, and NPM1 by stabilizing the interaction of EBNA2 with RBP-Jk. In a NPM1-knockdown cell line, we demonstrated that an
EBNA2-mediated transcription defect was fully restored by the ectopic expression of NPM1. Our findings highlight the
essential role of NPM1 in chaperoning EBNA2 onto the latency-associated membrane protein 1 (LMP1) promoters, which is
coordinated with the subsequent activation of transcriptional cascades through RBP-Jk during EBV infection. These data
advance our understanding of EBV pathology and further imply that NPM1 can be exploited as a therapeutic target for EBV-
associated diseases.
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Introduction
EBV is a human c-herpesvirus that infects both epithelial cells
and B lymphocytes, and it has been implicated in several human
malignancies, including Burkitt’s lymphoma (BL), Hodgkin’s
lymphoma, lymphoproliferative disease in immune-suppressed
patients, nasopharyngeal carcinoma (NPC), and some cases of
gastric cancer. The primary infection of B lymphocytes by EBV in
vitro readily leads to the establishment of immortalized lympho-
blastoid cell lines (LCLs) via the expression of a unique set of viral
genes, including six EBV nuclear antigens (EBNAs), three latency-
associated membrane proteins (LMPs), Bam A rightward tran-
scripts, and small non-coding RNAs [1]. Among the EBV latency
gene products, EBNALP, EBNA1, EBNA2, EBNA3A, EBNA3C
and LMP1 are critical for LCL cell transformation and
maintenance. During the initial stage of B cell infection by EBV,
the W promoter (Wp) is exclusively employed to drive the
transcription of EBNA2 and EBNALP genes, which are produced
by the alternative splicing process. Switches in the usage of Wp to
the C promoter (Cp) and activation of Cp by expression of EBNA2
and EBNALP subsequently leads to the concomitant expression of
other EBNAs and LMPs that are essential for the latent infection
and persistence of EBV {for reviews, see [1]}.
The activation of cellular and viral genes by EBNA2 is
coordinated with its biological role in supporting EBV-mediated
conversion of resting B cells into LCLs [1]. In general, EBNA2
engages in transcription activation through interactions with
cellular DNA-binding proteins, including RBP-Jk, PU.1, and
AUF1, which are tethered to the cognate responsive elements
[2,3,4,5]. The C-terminal acidic domain (AD) of EBNA2 recruits
the basal transcription machinery, which then performs a major
role during transcription activation by forming a transcriptional
PLOS Pathogens | www.plospathogens.org 1 December 2012 | Volume 8 | Issue 12 | e1003084pre-initiation complex (PIC) [6,7,8,9]. The N-terminus harbors
the second activation domain, which plays another role in
promoter up-regulation and LCL cell maintenance [10,11].
Furthermore, the survival motor neuron protein (SMN), co-
activators, such as p300/CBP, PCAF, p100 and SKIP1, and the
hSWI/SNF chromatin remodeling complex have all been shown
to facilitate EBNA2-dependent transcription via interactions with
EBNA2 [12,13,14,15,16,17]. Although the mechanism by which
EBNA2 activates its target genes has been intensively studied over
decades, the host factors that are required in addition to the basal
transcription machinery and the transcription co-activators that
are involved in EBNA2-mediated transcription remain poorly
understood.
Nucleophosmin (NPM1, also known as protein B23, NO38, or
numatrin) was originally identified as an abundant nuclear
phosphoprotein that resides in the nucleolus. It has attracted
significant attention for its multifunction capabilities in nuclear
shuttling, DNA-histone and nucleosome assembly, biogenesis of
ribosomal RNA, regulation of cell growth, DNA repair, cell
proliferation, and transformation [18,19,20,21,22,23,24,25]. The
fact that NPM1 is frequently mutated, rearranged, and overex-
pressed in hematological disorders has led investigators to propose
that NPM1 could be a proto-oncogene [21]. By contrast, NPM1
interacts with HDM2 to protect p53 from degradation, and its
absence results in mislocalization and protein instability of the
tumor suppressor ARF, suggesting an additional role for NPM1 in
tumor suppression [26,27]. At the moment, NPM1 is believed to
employ sophisticated mechanisms to engage in oncogenic and
tumor suppressor pathways [28].
By acting as a molecular chaperone, NPM1 is able to modulate
chromatin assembly and facilitate the DNA binding of the primary
transcription factors to their responsive elements, which consequent-
ly promotes the transcription of their target genes [22,25,29]. In this
study, we identified NPM1 as one of the cellular proteins bound to
EBNA2 using a protein affinity pull-down assay followed by liquid
chromatography-mass spectrometry (LC-MS/MS) analysis. The
physicalinteraction mediatedbyEBNA2and NPM1wasextensively
characterized, which was proposed as the major determinant of PIC
assembly. Finally, we provided striking evidence to show that ATP-
charged NPM1 does indeed act as a chaperone to escort EBNA2 to
couple with RBP-Jk at the LMP1 promoter in order to initiate the
subsequent EBNA2-dependent transcription, leading to the estab-
lishment and maintenance of EBV latency in B cells.
Results
NPM1 binds to EBNA2 both in vitro and in vivo
To explore the mechanism of EBNA2-mediated transcription in
EBV-transformed B cells, we initially aimed to investigate the
protein-protein interaction map of EBNA2. We expressed and
purified GST and GST fusion proteins with overlapping EBNA2
open reading frames (ORFs) (GST- E2s), including amino acids
(aa) 1–103, 96–210, 200–334, 300–432, and 426–465 (AD), which
covered almost the entire EBNA2, from E. coli. Affinity matrices
were used to pull down cellular proteins from IB4 cell lysates
(Figure 1 A–C). GST-E2 300–432 pulled down a unique protein
band with a molecular weight approximately 33 kD (Figure 1B).
LC-MS/MS identified this band as NPM1 with peptide sequences
covering 19% of the NPM1 ORF (Figures S1 A and B). Proteins
pulled down by the same bait were followed by immunoblotting
with the NPM1-specific antibody, which further validated this
interaction (Figure 1C).
To characterize the physical interaction mediated by EBNA2
and NPM1 in a physiologically relevant environment, we
performed co-immunoprecipitation (co-IP) and immunofluores-
cence (IF) confocal microscopy analyses. In IB4 LCL, NPM1 and
EBNA2 antibodies were used to immunoprecipitate approximately
0.8% of endogenous EBNA2 and NPM1, and the protein complex
formed by EBNA2 and NPM1 was not affected by RNaseA
treatment (Figure 1D), excluding the possibility that cellular RNAs
might act as an intermediate bridge to link the two proteins
together. Furthermore, EBNA2 and NPM1 mostly co-localized in
the nucleoplasm of the lymphoblastoid cells (Figure 1E, upper
panel). HeLa cells transfected with both GFP-NPM1 and EBNA2
expression vectors also showed a pronounced nuclear co-
localization (Figure 1E, lower panel), indicating a substantial
physical interaction mediated by EBNA2 and NPM1 that took
place in vivo.
The physical interaction of EBNA2 with NPM1 is
mediated by EBNA2 aa 300–360 and the N-terminal OD
of NPM1
To identify the core of the NPM1-binding domain located
within EBNA2 aa 300–432, GST and GST-E2 fusions that
contain small portions of the EBNA2 ORF, including aa 300–335,
335–360, 300–360, and 360–432, were next used in a protein
affinity pull-down assay (Figure 2A). Approximately 2.5% of
endogenous NPM1 was pulled down by GST-E2 300–360;
however, neither GST nor the remaining GST-E2s was shown
to possess any detectable NPM1 binding potency.
GST-E2 300–360 was further utilized as the protein matrix to
pull down ectopically expressed flag-tagged NPM1 (FNPM1) and
five truncated deletion mutants, including C1 (1–257), C2 (1–194),
C3 (1–120), N1 (120–294), and N2 (194–294) [30]. Among the
exogenous proteins, including FNPM1 and its mutants, approx-
imately 2% of FNPM1, C1, C2, or C3 was associated with GST-
E2 300–360, whereas neither N1 nor N2 was pulled down by the
same protein bait (Figure 2B). The N-terminus of NPM1 contains
highly conserved amino acid residues that are typically found in
members of the nucleophosmin family, which have been
Author Summary
Epstein-Barr Virus (EBV) infects human B cells to establish a
permanent infection in hosts, which can cause diseases
ranging from infectious mononucleosis to a broad
spectrum of human malignancies. The conversion of
human primary B cells into indefinitely proliferating
lymphoblastoid cell lines (LCLs) by in vitro EBV infection
provides a suitable model for virus-mediated cellular
transformation. Epstein-Barr nuclear antigen (EBNA) 2-
mediated transcription is essential for the establishment
and maintenance of EBV latent infection. In this report, we
have extensively explored the mechanism by which EBNA2
activates the latency-specific LMP1 promoter to establish a
permanent infection in B cells. We have identified and
characterized the protein-protein interaction of EBNA2
with the nuclear shuttle protein nucleophosmin (NPM1) in
vivo and in vitro. In particular, we have determined that
the expression of NPM1 is promptly induced upon EBV
infection and that EBNA2 has a role in activating NPM1
gene expression. Furthermore, we have shown that
oligomerized NPM1 is charged by ATP and binds to
EBNA2, which is crucial for its ability to stabilize its
interaction with the DNA binding protein RBP-Jk, which is
in turn essential for supporting the transcriptional
cascades of EBV latent infection. Our findings provide
striking evidence to illustrate a new model for under-
standing EBV pathology.
NPM1 Is Essential for EBV Latency Program III
PLOS Pathogens | www.plospathogens.org 2 December 2012 | Volume 8 | Issue 12 | e1003084Figure 1. Protein-protein interactions mediated by EBNA2 and NPM1 in vitro and in vivo. A). Schematic depiction of the GST-EBNA2
fusion proteins (GST-E2s). B). IB4 cell lysates were pulled down by similar amounts of each protein bait and resolved on a 4–20% gradient SDS-PAGE
gel. Unique gel bands were visualized by staining with Coomassie blue and excised for LC-MS/MS analysis. The NPM1 band is marked with arrowhead
6. C). The samples prepared in (B) were additionally immunoblotted with the NPM1 antibody. The amounts of GST or GST-E2 fusions were determined
by Coomassie blue staining, and each is marked with an individual asterisk. D). IB4 cells (10
7) were subjected to IP analysis using antibodies for EBNA2
(PE2), NPM1 (C-19), or IgG control, and the immunoprecipitated proteins were identified by Western blot with 2% input of EBNA2 and NPM1 as
loading controls. The relative expression of each protein was quantified by UN-scan and determined as a percentage of input. E). The
immunofluorescent (IF) analyses were carried out using antibodies for EBNA2 (v-C20) and NPM1 (C-19) followed by counterstaining with a goat anti-
mouse antibody conjugated to FITC (Green) or a donkey anti-goat antibody conjugated to rhodamine (red). Confocal images for EBNA2 (E2; Red) and
NPM1 (Green) from LCL (upper panels) or HeLa cells (bottom panels) that had been co-transfected with EBNA2 and GFP-NPM1 expression vectors are
shown. Nuclei were counterstained with DRAQ5 (blue).
doi:10.1371/journal.ppat.1003084.g001
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information, the transfected flag-tagged oligomerization-defective
mutants L102A and G105A and another oligomerization-compet-
itive mutant, S106A [23], were subjected to additional co-IP and
protein affinity pull-down analyses. In each transfection assay,
plasmid-expressed FNPM1 or three point mutants were expressed
at similar levels and efficiently immunoprecipitated by the flag-
specific antibody. Approximately 2% of endogenous NPM1 was
co-immunoprecipitated with FNPM1 and S106A, while fairly small
and barely detectable amounts of this protein were co-immuno-
precipitated with L102A and G105A, respectively (Figure 2C; upper
panel). The interaction between exogenous FNPM1 and endog-
enous NPM1 was not affected by ectopically expressed EBNA2
(Figure 2C; lower panel). Interestingly, our result showed that
neither of the ectopically expressed NPM1 mutants was associated
with GST-E2 300–360 (Figure 2 B). Taken together, our data
reveal that the conserved oligomerization domain (OD) of NPM1
and EBNA2 aa 300–360 mediate the protein-protein interaction
between EBNA2 and NPM1.
NPM1 expression is induced in EBV positively infected B
lymphocytes
To address the possibility that NPM1 has a role in EBV-
associated malignancies, the expression levels of NPM1 from an
equal amount of BL, NPC, and LCLs cell lysates were assayed by
immunoblot analysis. We found that substantial amounts of
NPM1 were expressed in AKATA BL cells regardless of EBV
status. By contrast, only relatively low levels of NPM1 were
observed in EBV-infected NPC cells and the amounts of NPM1 in
EBV-negative NPC cells were at a barely detectable level
(Figure 3A). In addition to the hallmarks of the EBV latency III
program, EBNA2 and its target gene c-MYC, a robust activation
of NPM1 gene expression was also detected in four individual
LCLs, while none of the proteins (EBNA2, c-MYC and NPM1)
was detected in primary B cells. Quantitative real time PCR
(qPCR) further identified that the mRNA levels of NPM1 were
activated by 2- to 3.5-fold in LCLs in comparison to primary B
cells (Figure 3B). A transfected NPM1 reporter plasmid (NPM1-
Luc) was consistently induced by EBNA2 to reach 4-fold
activation, and EBNALP co-activated the EBNA2 effect to result
in 8-fold total activation, which further up-regulated EBNA2-
inducing NPM1 promoter activity by 2-fold (Figure 3C). Further-
more, a 1.7-fold increase in the NPM1 protein expression level was
detected in BJAB cells that were stably expressing EBNA2 (BJAB-
E2) in comparison with the basal level identified in control BJAB
cells (Figure 3D). These results indicate that EBNA2 and EBNALP
have a major role in activating NPM1 transcription in EBV-
transformed B cells.
To verify that the induction of NPM1 in lymphoblastoid cells is
directly associated with EBV infection, the expression patterns of
NPM1, EBNA2, and c-MYC control in primary B cells were
monitored by microscopy or flow cytometry-mediated IF analysis
after 0, 3 or 7 days of virus or mock infection. As expected, only
the background signals of EBNA2, c-MYC, and NPM1 were
detected in mock-infected B cells from 0 to 7 days. EBNA2, the
key activator of EBV latent infection, began to be expressed in
approximately 18% of B cells at 3 days post-infection (dpi) and
increased to 26–30% at 7 dpi (Figures 3 E, F, S2A–B, and Table
S1). The immunostained spots of c-MYC appeared in 14.86% of B
cells at 3 dpi and increased to 27.06% at 7 dpi (Figures 3F, S2B,
and Table S1). Similarly, NPM1-positive cells were observed in
12.76% of B cells and increased to 19.92% at 7 dpi (Figures 3 E, F,
S2A, and Table S1). Notably, the c-MYC- or NPM1-expressing
cells were all detected in EBV positively infected B cells, indicating
an absolute dependence of c-MYC and NPM1 expression on EBV
infection. Finally, we showed consistent expression of both c-MYC
and NPM1 in a newly established LCL rather than in primary B
cells (Figures 3G and S2C), which further validated the hypothesis
that NPM1 expression induction was highly associated with EBV
infection.
NPM1 is essential for EBNA2-mediated transcription
The fact that NPM1 has a role in transcription up-regulation via
its associations with histone proteins inspired us to investigate
whether NPM1 is involved in EBNA2-mediated transcription
[22]. In transfection-mediated EBNA2-dependent transcription
assays, the expression levels of EBNA2 were not affected by the co-
transfected FNPM1 or any other NPM1 mutants (Figures 4 A and
B). EBNA2-inducing LMP1-Luc activity was maintained at 8- to
12-fold activation. We showed that neither the transfected FNPM1
nor any of the NPM1 mutants could affect the basal activity
produced by the LMP1-Luc reporter plasmid alone. Ectopic
expression of FNPM1 readily augmented the EBNA2-dependent
LMP1-Luc activity to reach an average of 20- to 25-fold total
activation, which induced a 2.5-fold co-activating effect
(Figure 4A). Similarly, the transfected C1, C2, or C3 elicited a
2.5-fold increase over the intrinsic EBNA2-inducing LMP1-Luc
activity. By contrast, neither ectopically expressed N1 nor N2 was
able to co-stimulate with EBNA2, indicating that NPM1 N-
terminal aa 1–120 contributed the major transcriptional up-
regulating effect. Following the loss of the EBNA2 binding
affinities found in the NPM1 mutants L102A, G105A, and S106A,
we next investigated their potency in co-stimulation with EBNA2.
Although plasmid-expressed FNPM1 co-stimulated with EBNA2
by 2.5-fold, we found that all transfected NPM1 mutants lost the
ability to up-regulate the EBNA2-inducing LMP1-Luc activity
(Figure 4B). These data reveal that NPM1-mediated self-associa-
tion and interaction with EBNA2 are the prerequisite require-
ments for co-stimulation with EBNA2.
Both ChIP and streptavidin-agarose-mediated DNA pull-down
analyses were further employed to gauge the abundance of NPM1
at the EBV latency-associated LMP1 promoter [31]. The amounts
of EBNA2 and NPM1 bound to this cognate promoter were
identified as 6% and 2% of the input DNA by PCR (Figure 4C). In
Figure 2. EBNA2 aa 300–360 and the NPM1 N-terminal OD are responsible for the specific physical interaction between the two
proteins. A). Schematic diagram of the GST-E2s used in this assay. The Coomassie-blue stained image for GST and GST-E2 fusion proteins (marked
with asterisks). The amounts of endogenous NPM1 from the IB4 cell lysate pulled down by the corresponding protein baits were assayed by
immunoblot analysis. Five percent input of NPM1 is shown. B). Schematic depiction of the flag-tagged wild type (FNPM1), truncated deletion, and
point mutants of NPM1. The conserved amino acid residues are shown in boldface, and the mutated sequences are underlined. BJAB cells (10
7)
transfected with 30 mg of the indicated expression vectors were subjected to protein affinity pull-down assays using GST 300–360 after 24 hours of
transfection. The amounts of transfected FNPM1 and other mutants bound to the protein bait were determined by immunoblot with the M2
antibody (a flag-tagged specific antibody). Two percent input of each was used as a loading control. C). 293T cells (2610
6) transfected with 3 mgo f
the FNPM1 or the indicated NPM1 mutants expression plasmids were used for M2-IP analysis after 24 hours of transfection. The interactions mediated
by endogenous NPM1 and the transfected FNPM1 or its mutant derivatives were determined (Lower panel). Two percent input of endogenous NPM1
is shown.
doi:10.1371/journal.ppat.1003084.g002
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mately 2% of endogenous EBNA2 and RBP-Jk and 5% of
endogenous NPM1 (Figure 4D), whereas neither of the proteins
was precipitated by the biotin-labeled or non-labeled control DNA
and the non-labeled LMP1 DNA. We then sought to explore
whether NPM1 is essential for EBNA2-mediated transcription. The
EBNA2-inducing LMP1-Luc activity was assayed in BJAB cells in
which endogenous NPM1 was stably silenced by the lentivirus-
expressed NPM1 shRNA (shNPM1-1 or shNPM1-2), or scrambled
shRNA. BJAB cell lines that stably expressed each shRNA, which
were designated as BJAB-shNPM1-1, BJAB-shNPM1-2, and BJAB-
scrambled, or control BJAB cells were subjected to transfection-
mediated reporter assays. The expression levels of the actin control
were not affected by any of the transduced shRNAs, so the amounts
of NPM1 detected in each cell line was expressed in relation to that
of the control BJAB cells, giving 71%, 99%, and 0% NPM1
knockdown efficiency in the BJAB- shNPM1-1, shNPM1-2, and
scrambled cell lines, respectively (Figure 4E). With similar
expression levels resulted by the transfected EBNA2, the EBNA2-
inducing LMP1-Luc activity could reach 6- and 8-fold activation in
the control and BJAB-scrambled cell lines, whereas this EBNA2-
dependent activity was reduced down to 3- and 1.5-fold activation
in the BJAB-shNPM1-1 and BJAB-shNPM1-2 cell lines. In
addition, the defect of EBNA2-mediated transcription caused by
the stable NPM1 depletion could not be restored by the co-
transfected EBNALP (Figure 4F). Our data reveal the dominant
importance of NPM1 in EBNA2-dependent transcription.
NPM1 stabilizes the interaction of EBNA2 with RBP-Jk to
induce the formation of a putative PIC
The fact that NPM1 has been shown to enhance chromatin
transcription by acting as a histone chaperone [22] inspired us to
hypothesize that NPM1 is involved in recruiting EBNA2 onto the
EBV latency-associated promoters. BJAB-E2 cells transduced with
shRNAs, as described in Figure 4E, were used to monitor the changes
in protein-protein interactions mediated by EBNA2 and RBP-Jk by
co-IP analysis. Endogenous EBNA2, RBP-Jk, and actin control were
expressed at similar levels, and both RBP-Jk and EBNA2 were
efficiently immunoprecipitated by their corresponding antibodies
from each cell lysate (Figure 5A). Our result showed that a 58%
knockdown of NPM1 decreased the amounts of co-immunoprecip-
itated RBP-Jk and EBNA2 to 28% and 21%, whereas 80% depletion
of NPM1 dissociated almost 100% of EBNA2 and RBP-Jk from the
immunoprecipitated protein complex. By contrast, the magnitude of
the physical interaction between EBNA2 and RBP-Jk that was
identified in the scrambled shRNA-expressing cells remained similar
to the level detected in control BJAB-E2 (Figures 5A–C). Moreover,
our results also indicated that NPM1 could associate with RBP-Jk
through its N-terminal OD (Figures 5A and S3), which further
suggested that NPM1 acted as a connecting bridge to stabilize the
interaction between EBNA2 and RBP-Jk.
To verify that NPM1 escorted EBNA2 to form a complex with
RBP-Jk at the EBV latency-specific LMP1 promoter, we next
performed a ChIP assay using EBNA2 and LMP1-Luc reporter co-
expressing BJAB cells (BJAB-E2/LMP1-Luc) that had been stably
transduced with shRNAs as described in Figure 4E. Lentivirus-
mediated expression of shNPM1-1 and shNPM1-2 effectively
depleted endogenous NPM1 by 81% and 97%, while the scrambled
shRNA remained ineffective in this cell line. Although EBNA2,
RBP-Jk,andactinwereexpressedatsimilarlevelsinthe controland
in all shRNA-transduced BJAB-E2/LMP1-Luc cell lines, NPM1
deficiencycausedanearlycompletedissociationofEBNA2fromthe
LMP1 promoter (Figure 5D). By contrast, the promoter occupancy
of RBP-Jk was not altered by NPM1 depletion. Our results suggest
that NPM1 has a role in the formation of a stable PIC.
The involvement of NPM1 in EBNA2-mediated
transcription is coordinated with the cell maintenance of
EBV-transformed lymphoblastoid cells
To verify that the involvement of NPM1 in EBNA2-dependent
transcription is coordinated with the subsequent maintenance of
lymphoblastoid cells, the expression levels of EBNA2 target genes
and cell proliferation were assayed using IB4 LCLs that had been
stably transduced with each type of shRNA as described elsewhere
in this article. In addition to actin, we found that the expression
levels of EBNAs, including EBNA2, EBNALP and EBNA1, and
RBP-Jk in the control cell line were similar to the levels of each
protein identified in either the NPM1 shRNA or the scrambled
shRNA expressing IB4 LCLs. As expected, the EBNA2 target
genes, such as c-MYC and LMP1, were expressed in a way that was
inversely correlated with the NPM1 knockdown efficiency
(Figure 5E). Although cell growth was slightly impaired by the
transduced scrambled shRNA, it remained similar to the phenotype
caused by the control IB4 LCL. Strikingly, the cell proliferation of
IB4 cells was halted when only 32% of the NPM1 expression was
retained, whereas these cells died over time when an 89%
knockdown efficiency of NPM1 was reached (Figure 5F). Similar
experiments were also conducted using the BJAB cell line and its
derivatives as described in Figure 4E. We found that the patterns of
cell growth were not altered by NPM1 depletion in the context of
BJAB cells (Figure 5G). These data strongly support the hypothesis
that NPM1-assisted EBNA2-dependent transcriptionislinkedtothe
concomitant maintenance of EBV-transformed B cells.
The ATP-bound state of NPM1 associates with EBNA2
and RBP-Jk to form the putative PIC
To assess the possibility that the ATP-bound state of NPM1
[32,33] is involved in the PIC formation, the amounts of EBNA2,
Figure 3. Activation of NPM1 expression is highly associated with EBV infection. A). The immunoblots for NPM1, EBNA2, c-MYC, and actin
control from EBV latently infected type I AKATA BL cells, type II HONE1 nasopharyngeal carcinoma cells (NPC), type III LCLs, and EBV negatively
infected AKATA, NPC HONE1, and primary B cells. B). The mRNA expression levels of NPM1 in primary B cells and four individual LCLs were
determined by quantitative real-time PCR (qPCR), respectively. The amount of NPM1 mRNA is expressed in relation to that of the GAPDH control. C).
The effects of EBNA2 and EBNALP on the NPM1-Luc reporter plasmid were determined by the transfection-mediated reporter assay. Error bars
represent the standard deviation from the mean for data from at least three independent experiments in this and subsequent figures. The
immunoblotting images for transfected EBNA2, EBNALP, and the actin control are shown. D). The expression levels of NPM1, EBNA2, and actin in
primary B cells, BJAB, or BJAB-EBNA2 were determined. E–F). Primary B cells (5610
4) were infected with EBV or PBS (Mock) and subjected to an IF
staining protocol using antibodies for EBNA2 (v-C20), NPM1 (C-19), or c-MYC at 0, 3 or 7 days after infection (dai) followed by a donkey anti-goat
antibody conjugated to FITC (Green) or a goat anti-mouse antibody conjugated to rhodamine (red). For mock infection, the Y-axis represented the
signaling resulted from a double staining procedure using c-MYC and NPM1 antibodies, whereas the X-axis represented the signaling resulted from
an EBNA2 immunostaining protocol. Nuclei were counterstained with DAPI. The immunostained cells were visualized by fluorescent microscopy and
quantified by flow cytometry (F). G). The newly established LCL (LCL-New), or previously established LCL (LCL1) and primary B cells were assayed for
EBNA2, c-MYC, and actin control expression levels.
doi:10.1371/journal.ppat.1003084.g003
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PLOS Pathogens | www.plospathogens.org 7 December 2012 | Volume 8 | Issue 12 | e1003084Figure 4. NPM1 is essential for EBNA2-inducing LMP1 promoter activity. A–B). The transfected FNPM1 and the indicated NPM1 mutants
were assayed for their effects on EBNA2-inducing LMP1-Luc activity after 24 hours of transfection. Immunoblots for ectopically expressed EBNA2 and
FNPM1s in this assay are shown. The resulting activity from each assay was represented as the mean 6 standard deviation for the data from three
NPM1 Is Essential for EBV Latency Program III
PLOS Pathogens | www.plospathogens.org 8 December 2012 | Volume 8 | Issue 12 | e1003084RBP-Jk, and NPM1 from IB4 cell lysates that were precipitated by
ATP or streptavidin-agarose were identified by immunoblot
analysis. Except for a-tubulin, we showed that approximately
0.4% of endogenous EBNA2, RBP-Jk, and NPM1 was pulled
down by ATP-agarose. By contrast, neither of the proteins was
precipitated by streptavidin-agarose (Figure 6A). The ability to
form a protein complex containing EBNA2, RBP-Jk, and NPM1
in IB4 cells was then monitored by co-IP assay after an ATP-
depletion protocol. Strikingly, although ATP-depletion partially
reduced the EBNA2 and BBP-Jk expression levels, it vigorously
dissociated each protein from the complex. By contrast, the stable
protein complex remained in its original form in the control IB4
cells (Figure 6B).
A ChIP assay was carried out to further verify that ATP-
depletion could impair the promoter occupancy of EBNA2, RBP-
Jk, and NPM1. In normal IB4 cells, a substantial level of
occupancy of each protein at the LMP1 promoter was identified
by both PCR and qPCR, which showed an average from 5% to
6% of the input DNA (Figures 6C and S4A). The abundance of
promoter-bound RBP-Jk was not altered while both EBNA2 and
NPM1 were almost completely dissociated from the LMP1
promoter in ATP-deficient cells. In addition, our result revealed
that the amount of acetylated H3 (H3ac) at the control GAPDH
promoter was not affected by ATP-depletion, accounting for 4%
of the input DNA (Figures 6C and S4B–C). To confirm that ATP-
depletion should consequently lead to the abrogation of EBNA2-
dependent transcription, the EBNA2-inducing LMP1-Luc activity
was assayed in BJAB cells with 0 to 2 hours of ATP-depletion.
Although the expression levels of the transfected EBNA2 and
endogenous actin were not altered within the ATP-depletion time
frame, a progressive loss of EBNA2-inducing activity was detected
upon ATP-depletion in a time-dependent manner (Figure 6D). On
the other hand, we demonstrated that the intrinsic activity of the
transfected SV40-Luc reporter plasmid was not affected by ATP-
depletion (Figure S4C).
To exclude the possibility that our findings could have resulted
from the nonspecific effects caused by cell ATP-deficiency, the
plasmids of two ATP-binding mutants, K263R and K257/263R [32],
were used to confirm that the ATP-bound state of NPM1 is indeed
required for the putative PIC formation following transfection-
mediated ATP-agarose pull-down, Co-IP, and reporter assays.
Our result showed that 2% of the transfected FNPM1 and three
previously identified EBNA2 binding mutants L102A, G105A, and
S106A (Figure 2B) were efficiently pulled down by ATP-agarose,
whereas plasmid-expressed GFP, K263R and K257/263R did not
possess any detectable ATP-binding affinity (Figures 6E–F; S4E).
The co-IP assay indicated that both ATP-binding mutants lost the
ability to associate with EBNA2, while the transfected FNPM1
remained effectively bound to EBNA2 (Figure 6G). Furthermore,
ectopic expression of the ATP-binding mutants did not cause any
co-stimulating effects on the EBNA2-inducing LMP1-Luc activity,
while the transfected FNPM1 vigorously augmented this EBNA2-
dependent activity by 4-fold (Figure 6H). Altogether, these results
suggest that NPM1 needs to be in an ATP-bound state to induce
the assembly of the PIC.
NPM1 binds to EBNA2 and recruits it to the latency-
specific LMP1 promoter
Finally, we aimed to provide direct evidence supporting the idea
that the recruitment of EBNA2 to the latency-specific LMP1
promoter relies on its interaction with NPM1. To this end, the
transfected FNPM1 and three types of EBNA2 binding mutants,
including G105A, S106A, and K257/263R, were monitored for their
ability to form a complex with EBNA2 at the LMP1 promoter in
BJAB/LMP1-Luc cells, respectively. The co-transfected EBNA2
and FNPM1, or its mutant derivatives, were expressed at similar
levels (Figure 7A). ChIP assays identified the accumulation of
FNPM1 at the LMP1 promoter at approximately 20-fold above
the background level found in the IgG control. In contrast, the
amount of promoter occupancy identified for each transfected
EBNA2-binding mutant was similar to that of the IgG control
(Figures 7A and S5). We noted that shNPM1-2 suppressed NPM1
mRNA by targeting its 39UTR, which allowed us to carry out the
plasmid-mediated rescue experiment for the EBNA2-dependent
transcription assay in the context of BJAB-shNPM1-2 cell line.
The co-transfected EBNA2, FNPM1, and three EBNA2 binding
mutants were expressed at similar levels. A complete loss of the
EBNA2-inducing activity of LMP1-Luc in BJAB-shNPM1-2 cells
was successfully restored by the co-transfected FNPM from the
background level to 10-fold activation, which was comparable to
the EBNA2-dependent transcriptional activity detected in BJAB-
scrambled cells. In comparison, neither of the transfected EBNA2
binding mutants was able to rescue the EBNA2-dependent
transcription defect of LMP1-Luc in BJAB-shNPM1-2 cells
(Figure 7B). These data imply that the ability of NPM1 to bind
to EBNA2 is the most important factor that determines the
EBNA2 abundance at its target promoter.
Discussion
Due to a lack of intrinsic DNA binding activity, the stable
association of EBNA2 with RBP-Jk has been characterized in each
EBNA2 target promoter, although the importance of the PU.1 or
AUF1 sites in the LMP1 promoter argues that the RBP-Jk sites are
insufficient to support all EBNA2-dependent transcription [1].
The potent interactions with both RBP-Jk and SKIP that are
mediated by the EBNA2 internal region aa 280–337 has long been
considered to be a direct force that induces the formation of the
PIC [2,13]. However, the mechanistic basis for this scenario has
yet to be elucidated. In this study, we identified the domain that
corresponds to EBNA2 aa 300–360 as the NPM1 binding module,
which contains a partial overlapping region within the RBP-Jk
binding domain. Oligomerization mediated by the N-terminal
region aa 1–120 of NPM1 is known to be coordinated with its
major chaperone activity, while the ATP-bound state of NPM1
depends on the sumoylation of the K263 residue, which was
previously implicated in protein stability, nuclear distribution, and
cell proliferation [32,34]. Our data reveal that not only the N-
terminal OD of NPM1 but also the oligomerized and ATP-bound
states of NPM1 are required for maintaining the specific
interaction with EBNA2.
individual experiments.
*P value.0.05 vs. control, and
**P value ,0.05. C). A schematic depiction of the cognate responsive elements located at the
LMP1 promoter. Promoter occupancy of EBNA2, NPM1, or the control flag-epitope antibody was identified by ChIP analysis using the corresponding
antibodies, i.e., PE2 for EBNA2, 5E3 for NPM1, and M2 for flag, and then quantified by PCR. D). Proteins bound to the corresponding DNA fragments
were identified by the streptavidin-agarose mediated pull-down assay followed by immunoblot analysis. Ten percent input of the DNA fragments
and 5% of each protein are shown. E). The EBNA2-inducing LMP1-Luc activity in each NPM1 knockdown cell line was determined by the transfection-
mediated reporter assay. The expression levels of the transfected EBNA2 in the control and shRNA transduced cell lines were verified by Western blot.
F). EBNALP co-activation with EBNA2-dependent transcription of LMP1-Luc was monitored in scrambled shRNA and shNPM1-2 expressing BJAB cells.
The immunoblots for the transfected EBNA2, EBNALP, endogenous NPM1, and the actin control are shown.
doi:10.1371/journal.ppat.1003084.g004
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PLOS Pathogens | www.plospathogens.org 10 December 2012 | Volume 8 | Issue 12 | e1003084The sophisticated functional profiles of NPM1 documented so
far have led to the difficulties in the delineation of its biological
picture. Nevertheless, the overexpression of NPM1 is found in
many types of solid human tumors, including tumors of the
thyroid, brain, liver, and prostate [34]. Induction of NPM1 by
mitotic agent treatments in B or T lymphocytes further echoes its
involvement in mitotic progression and cell proliferation [19,35].
Moreover, NPM1 has been identified as one of the c-MYC target
genes, and it potentially enhances c-MYC-induced hyperprolifera-
tion and transformation via a direct protein-protein interaction
[20,36]. Accordingly, we observed a pronounced induction of both
c-MYC and NPM1 in EBV positively infected B lymphocytes
throughout the duration of viral infection. This finding provides a
more comprehensive understanding of why c-MYC is one of the
major determinants of the EBV latency III program maintenance
[37,38]. Our results at least partially indicate that EBNA2 and
EBNALP play a role in the transactivation of NPM1, and this
effect could possibly be further augmented by the subsequent
expression of c-MYC. Additionally, the high levels of NPM1
observed in EBV negatively infected AKATA or BJAB BL cells
suggest that proliferating B cells constitute an additional means to
induce NPM1 expression in the absence of an EBV infection. This
assumption can also explain the observation that the NPM1-Luc
reporter activity induced by EBNA2 and EBNALP in BJAB BL
cells or the overexpressed level of enodogenous NPM1 in the
EBNA2 stably expressing BJAB cell line was simply shown as an
intermediate phenotype.
The main breakthrough of this study is that ATP-charged
NPM1 functions as a connecting bridge that links EBNA2 and
RBP-Jk together to form a complex at the EBV latency-specific
promoter LMP1, which implies that ATP-bound state of NPM1 is
involved in the formation of a stable PIC. In the absence of either
NPM1 or ATP, EBNA2 no longer binds to RBP-Jk and will
dissociate from the LMP1 promoter, while the DNA-binding
potency of RBP-Jk remains unaltered. Thus, the major contribu-
tion of NPM1 is that it acts as a chaperone to escort EBNA2 to its
target genes. Our findings fill in missing parts of the EBNA2-
dependent transcription model, which have been lacking from
previous studies. Because neither NPM1 nor EBNA2 possesses
bona-fide DNA-binding potency, the DNA-binding protein RBP-
Jk emerges as their intermediate instead. Nevertheless, EBNA2
alone remains insufficient in maintaining the interaction with
RBP-Jk and yet requires a prerequisite binding with NPM1 to
stabilize the subsequent interaction with RBP-Jk. In lymphoblas-
toid cells, the dominant importance of NPM1 in EBNA2-
dependent transcription further supports this proposed scenario.
Among the viral latent proteins that are involved in EBV-mediated
immortalization of B cells, the expression of LMP1 appears to be
highly dependent on EBNA2. As in the EBNA2 target gene c-
MYC, an enormous reduction in LMP1 expression was observed
in NPM1 knockdown lymphoblastoid cells, while the expression
levels of the remaining EBNAs, including EBNA1, EBNA2, and
EBNALP, RBP-Jk and the actin control were not altered. Most
importantly, the robust impairments of cell growth caused by
NPM1 knockdown in IB4 LCL emphasize the conspicuous
biological role of NPM1 in EBV latent infection.
According to our progress in this study, we have constructed the
following new model for the EBNA2-dependent transcriptional
cascades that are activated in EBV-immortalized B cells
(Figure 7C): (1) Entry of EBV into B cells occurs at the initial
stage of viral infection. (2) EBNA2 and EBNALP are transcribed
via activation of Wp. (3) Activation of NPM1 expression and other
EBNA2 and EBNALP-dependent genes, such as c-MYC, CD21,
and CD23. (4) Oligomerized NPM1 is charged by ATP to form
the ATP-bound state (which is the active form of NPM1). (5) RBP-
Jk is recruited to the binding sites that are located in the EBNA2
target promoters. (6) The active form of NPM1 binds to EBNA2,
escorts it to form a complex with RBP-Jk, and subsequently
induces the assembly of a PIC. (7) The EBNA2 C-terminal AD
mediates the recruitment of the basal transcription machinery
(BTM), transcription factors (TFs), and transcription cofactors
(TCs). (8) EBNALP binds to EBNA2 and augments EBNA2-
dependent transcription. (9) Expression of cellular and viral genes
that are essential for the establishment and maintenance of the
EBV latent infection occur.
The involvement of NPM1 in viral replication has been
documented in hepatitis delta virus, Japanese encephalitis virus,
and adenovirus [39,40,41]. Until recently, NPM1 phosphorylation
by v-cyclin-CDK6 was thought to be a critical event that was
linked to KSHV latency [42]. In addition, the acetylation of
NPM1 was further implicated in viral transactivation upon HIV
infection [43]. Accumulated evidence implies that NPM1 seems to
have co-evolved with the human viruses to facilitate diverse virus
infection processes within the nucleus. The fact that EBNA2
mimics an activated Notch receptor to drive transcription through
RBP-Jk during B cell immortalization [44] suggests the possibility
that NPM1 represents a prototype nuclear chaperone that is
involved in Notch-dependent transcription, although this hypoth-
esis has yet to be confirmed. Our studies open a new window for
exploring the molecular models of EBNA2 and Notch-dependent
transcriptional cascades. Moreover, our data additionally reveal
NPM1 to be a potent drug target for EBV-associated diseases.
Materials and Methods
Expression plasmids and cloning
The expression vector of the GST-EBNA2 (GST-E2) acidic
domain (AD) was previously described [8]. The remaining GST-
E2 expression plasmids were generated by subcloning the
indicated EBNA2 flanking sequences, which were amplified by
polymerase chain reaction (PCR) using the appropriate corre-
Figure 5. NPM1-mediated EBNA2 recruitment onto the LMP1 promoter is essential for the maintenance of lymphoblastoid cells. A).
NPM1-depletion, scrambled shRNA expression, or control BJAB-E2 cells were subjected to IP analysis using antibodies for EBNA2, RBP-Jk, and IgG
control, respectively. The expression levels of EBNA2, RBP-Jk, NPM1, and actin control in each cell line were determined by Western blot. The amounts
of EBNA2, BRP-Jk, and NPM1 contained in each immunoprecipitated protein complex and 2% input of each protein are shown. The immunoblotted
images were further quantified using UN-scan. The amounts of the indicated proteins identified in the NPM1 or scrambled shRNA knockdown cell
lines are expressed relative to the protein levels observed in the control cells. The relative amount of each protein is shown at the bottom of the
image. B–C). The summary of data from A (the first and fourth panels, respectively) is converted as a histogram showing the relative amounts of co-
immunoprecipitated RBP-Jk (B) or EBNA2 (C) from the indicated BJAB-E2 cell lines, which represents the magnitude of EBNA2 and RBP-Jk association.
D). BJAB-E2/LMP1-Luc cells transduced with the lentivirus-expressed NPM1 shRNAs or scrambled shRNA were subjected to a ChIP assay. Immunoblots
for the proteins of interest and actin control from each cell line are shown. The promoter occupancy of each protein was quantified by PCR. E). The
expression levels of the indicated proteins in each NPM1-depleted or IB4 LCL control were assayed by immune blot. F). IB4 LCL and its derivatives
described in (E) were measured for growth over five consecutive days. G). The growth curves represented for the shRNA knockdown and control BJAB
cells are shown.
doi:10.1371/journal.ppat.1003084.g005
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2TK (GE Healthcare). The expression vectors of flag-tagged wild
type NPM1 (FNPM1) or its derivatives of truncated deletion
mutants were gifts of Dr. Charles J. Sherff (Howard Hughes
Medical Institute and Department of Genetics & Tumor Cell
Biology, St. Jude Children’s Research Hospital). The flag-tagged
expression plasmids of the NPM1 point mutants were generated
using the QuikChange Site-Directed Mutagenesis Kit (Stratagene)
instruction manual. The GFP-NPM1 expression vector was
generated by inserting the entire coding sequence of NPM1 into
the XhoI and BamHI sites of eGFP-C1 (TakaraBio USA). The
expression vectors of EBNA2 (E2) and EBNALP (LP) and the
reporter plasmids LMP1-Luc and CMV-bGal were described
previously [10,45]. The reporter plasmid of NPM1-Luc was
generated by subcloning the promoter fragment 2910 to +49 into
the KpnI and XhoI sites of the PGL3 vector (Promega).
Cell culture, transfection, and cell-based reporter assays
IB4 is an EBV-transformed LCL [46], whereas LCL1-3 are
previously established cell lines from the laboratory. AKATA and
BJAB are EBV latently infected type I and non-infected Burkitt’s
Lymphoma (BL) cell lines [47,48]. Both LCLs and BL cell lines were
cultured in RPMI-1640 (Life Technology) supplemented with 10%
fetal calf serum (FCS) (R10 medium) (Biological Inc.), while HeLa and
293T cells were maintained in DMEM (Life Technology) supple-
mented with 10% FCS. For the ATP depletion assay, the culture
medium for IB4 or BJAB cells was replaced with glucose (2)
RPMI640 (Life Technology) supplemented with 10% FCS, 2 mM
deoxyglucose (Sigma), and 300 nM antimycin A (Sigma) and cultured
for 2 hours or the indicated time before the assays were completed.
The transfection procedure carried out in this study has been
previously described [9,45]. The EBNA2 and LMP1-Luc reporter
co-expressing BJAB stable clones were established by co-transfec-
tion of pSG5-EBNA2 (E2), LMP1-Luc, and pIRES-puro (Takar-
aBio USA) expression plasmids into BJAB cells and selected with
5 ng/ml puromycin. HeLa (2610
5) were transfected with 0.5 mg
of the GFP-NPM1 and EBNA2 expression vectors, whereas 293T
cells (2610
6) were transfected with 3 mg FNPM1 or its derivative
mutant expression vectors and 3 mg E2 or control empty vector
using Lipofectamine 2000 (Life Technology) following the
manufacturer’s protocol. For the EBNA2-inducing LMP1-Luc
activity assay, appropriate amounts of the necessary expression
vectors, LMP1-Luc reporter plasmid, and internal control CMV-
bGal plasmid were co-transfected into BJAB cells or NPM1
knockdown cells under the indicated circumstances. Luciferase
and b-Gal activities were assayed by Orion L (Berthold). The data
are represented as the mean 6 the standard error of the mean
(SEM) from three independent experiments. Whenever necessary,
statistical comparisons were performed by one-way ANOVA
variance analyses. A p-value of less than 0.05 was considered to be
statistically significant.
Production of the recombinant proteins and the protein
binding affinity assay
GST or GST-E2s were expressed in E. coli BL21 (DE3) pLys
strain (Stratagene) and purified by affinity chromatography
analysis using GST-sepharose (GE Healthcare), and each of the
purified recombinant proteins was used as the protein bait to pull
down proteins from IB4 cell lysates. Furthermore, cell lysates from
BJAB cells that had been transfected with 30 mg of flag-tagged
empty vector, wild type, or the indicated truncated deletion
mutants of NPM1 were further employed for protein affinity pull-
down assays using GST and GST-E2 aa 300–360 recombinant
proteins. The cellular proteins that were bound to each of the
GST-E2s were analyzed by SDS-polyacrylamide gel electropho-
resis (SDS-PAGE) followed by LC-MS/MS (Protech Taiwan) or
immunoblot analysis.
Primary B cell isolation and EBV infection
Primary B cells wereisolated from peripheral blood mononuclear
cells (PBMC) using Dynabeads Untouched (Life Technologies)
following the manufacturer’s suggested protocol. EBV infectious
particles were induced and purified from the B95-8 Z-HT cell line
as previously described [49]. Primary B cells (5610
4 per 100 ml)
were resuspended in RPMI 1640 supplemented with 15% fetal calf
serum (FCS), 2 mM L-glutamine, and penicillin/streptomycin and
aliquoted into a 96-well plate. One hundred microliters of virus or
PBS (mock infection) was used for each infection.
Immunofluorescence microscopy and flow cytometry
Immunofluorescence (IF) analysis was performed according to
the immunostaining protocol described previously [50] using the
EBNA2, NPM1, and c-MYC-specific antibodies vC-20 (Santa
Cruz), C-19 (Santa Cruz), and a c-MYC (Millipore), respectively.
In the co-immunostaining assay, rhodamine-conjugated goat anti-
mouse and FITC-conjugated goat anti-rabbit (Kirkegaard & Perry
Laboratories, Inc.) antibodies were used as fluorochromes, and
DNA was counterstained with DRAQ5 (Bio Status) or DAPI
(Sigma).
The nuclear co-localization of EBNA2 and NPM1 was
visualized by confocal microscope (LEICA TCS SP2 AOBS).
For the virus infection assay, primary B cells infected with EBV or
mock (PBS) were immunostained with the appropriate antibodies
followed a counterstaining protocol with the corresponding
secondary antibodies, which were conjugated with FITC or
rhodamine. The immunostained cells were visualized using the
Cell Imaging Station (Life Technologies) or analyzed by Guava
flow cytometry (Millipore).
Lentiviral vector production and cell transduction
Lentiviral shRNA expression plasmids of NPM1 were pur-
chased from the National RNAi Core Facility at Academia Sinica,
Taiwan. The production of the shRNA-expressing lentiviral
Figure 6. ATP-charged NPM1 induces the assembly of the putative PIC. A). Proteins bound to ATP or control streptavidin-agarose were
assayed by immune blot. Two percent input of each protein is shown. B–C). IB4 cells treated with or without ATP depletion were subjected to IP and
ChIP analyses exactly as described in Figure 5A and 5D. The immunoblots for the immunoprecipitated, co-immunoprecipitated proteins, and 5%
input of the proteins for each assay are shown. The promoter occupancy of each protein was quantified by both PCR and qPCR. Data from qPCR were
formulated as a percentage of the input DNA. The abundance of H3ac was assayed for the GAPDH promoter. D). EBNA2-inducing LMP1-Luc reporter
activity in BJAB cells that were treated with ATP-depletion over different time courses are shown. The expression levels of the transfected EBNA2 and
the actin internal control at different time points were determined. E–F). A schematic representation of the ATP-binding mutants, K263R and K257/263R.
293T cells transfected with the expression plasmid of FNPM1, FNPM1 mutants, or GFP were used for an ATP-agarose-mediated pull-down assay
followed by an immune blot with M2 or GFP antibody. Five percent input of GFP and FNPM1s are shown. G). The interaction between EBNA2 and
FNPM1, or each FNPM1 mutant, was identified by co-IP and Western blot. Two percent input of EBNA2 and FNPM1s are shown. H). The up-regulating
effects caused by the transfected FNPM1 or two ATP binding mutants on EBNA2-dependent transcription are shown. The expression levels of
ectopically expressed EBNA2 and FNPM1s in each assay were determined.
doi:10.1371/journal.ppat.1003084.g006
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PLOS Pathogens | www.plospathogens.org 13 December 2012 | Volume 8 | Issue 12 | e1003084Figure 7. NPM1 binds to EBNA2 and recruits it to the EBV latency-specific LMP1 promoter. A). BJAB-LMP1-Luc cells co-transfected with
the plasmids of EBNA2 and FNPM1 or EBNA2 binding mutants were subjected to ChIP assay using M2 antibody or control IgG. The immunoblots for
the transfected EBNA2 or FNPM1s are shown. Promoter occupancy of FNPM1 or other mutants was quantified by qPCR. In each case, the data from
M2 ChIP were normalized to the background level that was identified for IgG ChIP. B). The transfected FNPM1 and each FNPM1 mutant were used to
rescue the defect in EBNA2-dependent transcription of NPM1 knockdown cells. The intrinsic EBNA2-inducing LMP1-Luc activity observed in BJAB-
scrambled cells was used as a positive control. The expression levels of the transfected plasmids, endogenous NPM1, and actin control for each assay
are shown. C). A new version of the working model proposed for EBNA2-dependent transcription in EBV immortalized B lymphocytes.
doi:10.1371/journal.ppat.1003084.g007
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manufacturer. To silence NPM1, 5610
5 BJAB BL cells or IB4
cells per ml were cultured in six-well culture dishes and transduced
with 1 ml of lentivirus supernatant in the presence of 8 mg/mL of
polybrene. Each transfectant was replenished with new media
48 hours after transduction and maintained for another 48 hours,
followed by selection with 5 ng/ml of puromycin.
Chromatin immunoprecipitation (ChIP), streptavidin and
ATP-agarose mediated pull-down analyses
IB4 cells or EBNA2/LMP1-Luc co-expressing BJAB cells stably
transducedwithNPM1 shRNAsorscrambledshRNA(1610
7)were
subjectedto anenzymatic shearingprotocol (Active motif) suggested
by the manufacturer followed by a subsequent chromatin immu-
noprecipitation (ChIP) analysis using antibodies for NPM1 (5E3;
from Abcam), EBNA2 (PE2; from Abcam), or RBP-Jk (from
Genetext). The promoter occupancy of EBNA2, NPM1, and RBP-
Jk was monitored by PCR or quantitative PCR (qPCR) analysis for
the corresponding promoter fragments. The primers for this assay
are listed in Figure S4C. The ChIP assay kit for GAPDH control
was purchased from Millipore. The protocol for qPCR was
performed using the Eco Real-Time PCR system (Illumina) as
previously described [31]. The promoter occupancy that was
identified for each protein or IgG control was normalized by the
input DNA and formulated as a percentage of the input DNA. On
the other hand, the promoter occupancy of transfected FNPM1 or
its mutants were normalized to the IgG control. The LMP1
promoter DNA or control oriP DNA was amplified by PCR using a
pair of the corresponding biotin-labeled or non-biotin-labeled
primers [31]. Cell lysates from 1610
7 or 1610
8 IB4 cells were
prepared and subjected to a streptavidin (Life Technology) or an
ATP-agarose (Sigma) -mediated pull-down assay. The proteins that
were bound to each target DNA fragment or ATP-agarose were
monitored by immunoblotting with the appropriate antibodies.
Measurements of cell proliferation
Normal IB4 LCL and NPM1 knockdown IB4 cells (5610
4 per
200 ml) or BJAB cells and NPM1 knockdown BJAB cells (10
4 per
200 ml) were aliquoted in triplicate into 96-well plates. Viable cells
were counted using the trypan blue exclusion method every
24 hours for five consecutive days.
Supporting Information
Figure S1 The protein-protein interaction map of
EBNA2, as it relates to Figure 1. A). Cellular proteins from
IB4 cell lysates pulled down by GST or GST-E2s were subjected
to 4–20% gradient SDS-PAGE gel and visualized with Coomassie
blue staining. Specific bands are marked with individual
arrowheads. B). The proteins contained in each unique gel band
were identified by LC-MS/MS analysis. The description of the
proteins identified in each gel band and the coverage of the
peptide sequences for the corresponding proteins are shown.
(PPT)
Figure S2 Expression of NPM1 and c-MYC is induced in
EBV-infected B cells, in relation to Figure 3. A). Primary B
cells (5610
4) were infected with EBV or PBS (mock) and subjected
to an IF staining protocol for monitoring the expression of EBNA2
(Green) and NPM1 (Red) at 3 or 7 dai. Nuclei were counterstained
with DAPI. The immunostained cells were visualized with
fluorescence microscopy and quantified by flow cytometry (See
table S1). B). The same protocol that was described in (A) was
carried out to identify the expression of EBNA2 (Green) and its
target gene c-MYC (Red). Both color and grayscale images are
shown.C). Co-immunostaining of the newly established LCL (LCL-
New) or primary B cells using antibodies for EBNA2 and NPM1.
The immunostained cells were visualized by confocal microscopy.
(PPT)
Figure S3 The EBNA2 binding domain of NPM1 associ-
ated with RBPJ, in relation to Figure 5. BJAB cells
transfected with the expression vector of FNPM1 or its truncated
deletion mutant derivatives were subjected to M2-sepharose-
mediated IP analysis followed by immunoblotting with antibodies
for the flag epitope (M2) and RBPJ. Two percent input of
endogenous RBPJ is shown.
(PPT)
Figure S4 Dissociation of EBNA2 and NPM1 from the
cognate response elements by ATP-depletion, in relation
to Figure 6. A). The accumulation of EBNA2, NPM1, RBPJ,
and control IgG at the LMP1 promoter in IB4 cells treated with or
without ATP-depletion was identified by ChIP-qPCR assay.
Relative promoter occupancy of each protein is expressed as a
percentage of the input DNA. B). The same protocol that was
described in (A) was used to identify the abundance of H3ac at the
GAPDH promoter. Error bars represent the standard deviation of
triplicate samples for this and subsequent ChIP assays. C). The list
of primers used for qPCR assay in this study. D). Transfection-
mediated SV40-Luc reporter assay was performed using BJAB
cells. Treatment of ATP-depletion was performed at 0.5, 1, 1.5,
2 hours before the luciferase activity assay. The activity of the
transfected SV40-Luc reporter plasmid was normalized by the b-
gal activity produced by the internal control CMV-b-gal. E). 293T
cells that were transfected with each of the expression vectors of
GFP, FNPM1, and EBNA2 binding mutants L102A, G105A, and
S106A were subjected to ATP-agarose-mediated pull-down assay,
respectively. Five percent input of each protein is shown.
(PPT)
Figure S5 NPM1 binds to EBNA2 and recruits it to the
EBV latency-specific LMP1 promoter, in relation to
Figure 7. BJAB-LMP1-Luc cells were co-transfected with the
expression plasmids of EBNA2 and FNPM1 or each EBNA2
binding mutants G105A, S106A, K257/263R were subjected to M2-
ChIP assay. The accumulation of each protein at the LMP1
promoter is expressed in relation to its background level of IgG.
(PPT)
Table S1 The EBV infection assay. Primary B cells (5610
4)
were infected with EBV or PBS (Mock) and subjected to an IF staining
protocol using antibodies for EBNA2 (v-C20), NPM1 (C-19), or c-
MYC at 0, 3 or 7 days after infection (dai) followed by a donkey anti-
goat antibody conjugated to FITC (Green) or a goat anti-mouse
antibody conjugated to rhodamine (red). Nuclei were counterstained
with DAPI. The immunostained cells were quantified by flow
cytometry. The summary data from immunostaining assays are shown.
(PPT)
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